Browse diseases

…nd 55.68%, respectively), and among primary cancers, those with breast cancer, multiple myeloma, and lung cancer reported the highest prevale…

…fficacy of memantine, an antagonist of N-methyl-D-aspartate, in CIPN management.Methods This double-blinded randomised clinical tria…

…dependent manner, indicating alleviation of neuropathic pain in CIPN. No significant body weight loss was observed across treatment …

…cacy for symptom relief, however evidence is limited to painful CIPN, which is a phenotype experienced by less than half of all CIPN…

…Introduction Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent non-haematological, dose-limiting advers…

…ment light chain (sNfL) could predict the onset and severity of CIPN, and whether sNfL levels were associated with other clinical fa…

…umber of pain conditions, the mechanisms supporting its use for CIPN remain to be elucidated. Thus, we aimed to examine whether SCS …